HAITONG INT'L: Initiates Lens Technology (06613) with a "outperform" rating and a target price of 36.5 Hong Kong dollars.
Blue Technology, as a leading platform-type company in the intelligent terminal industry chain, is fully benefiting from the innovation cycle of major customers. In addition, smartphones and computers are expected to benefit from the innovation cycle of major customers in the next three years, with high business visibility. It is expected to accelerate growth.
HAITONG INT'L released a research report stating that Lens Technology (06613) was given a "outperform" rating with a target price of 36.5 Hong Kong dollars, representing a 46.7% upside potential. The report indicates that Lens Technology, as a leading platform in the smart terminal industry chain, is benefiting from the innovation cycle of large customers, and is expected to accelerate growth in the next three years, especially in the smart phone and computer sectors.
The firm believes that the group's business is expected to accelerate growth in the coming years, and profits are expected to increase faster than revenue. In addition, it is projected that the group's revenue will reach 87.407 billion, 110.547 billion, and 133.141 billion RMB in 2025, 2026, and 2027 respectively, with net profits attributable to shareholders reaching 4.785 billion, 6.801 billion, and 8.362 billion RMB.
Related Articles

On November 4th, STANCHART (02888) spent 7.606 million pounds to repurchase 481,000 shares.

KML TECH (08065) issues profit warning, expecting a mid-term pre-tax loss of approximately HK$4.5 million.

HAOHAI BIOTEC (06826) spent HK$805,700 to repurchase 29,600 shares on November 5th.
On November 4th, STANCHART (02888) spent 7.606 million pounds to repurchase 481,000 shares.

KML TECH (08065) issues profit warning, expecting a mid-term pre-tax loss of approximately HK$4.5 million.

HAOHAI BIOTEC (06826) spent HK$805,700 to repurchase 29,600 shares on November 5th.

RECOMMEND

World’s largest oil company Aramco posts higher Q3 net profit after lifting output
04/11/2025

HSBC, General Atlantic CEOs flag AI capex-revenue mismatch, ‘irrational exuberance’
04/11/2025

Pfizer Files Second Lawsuit Against Novo Nordisk and Metsera Amid Intensifying Bidding Battle Over Obesity Biotech
04/11/2025


